INTRODUCTION
Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin's lymphoma (NHL), which in the sporadic form-the subtype seen in Western Europe and North America-accounts for 1-2% of all adult lymphomas. BL often presents with bulky extranodalespecially abdominal-disease, leukemia, central nervous system (CNS) involvement and a rapidly progressive clinical course. There is a characteristic histology and a germinal center immunophenotype.
1,2 A high proliferation index with a Ki67 expression of nearly 100% is characteristic, and the hallmark of the tumor is a rearrangement involving MYC due, in 80% of cases, to t(8;14)(q24;q32). 3 Immunodeficiency associated BL occurs in HIVpositive (HIV þ ) patients, accounting for 30% of lymphomas seen in these patients. The endemic form of BL is seen mainly in Africa.
The entity previously known as Burkitt-like lymphoma (BLL) is an aggressive NHL with similarities to BL and one that is at times morphologically indistinguishable from the latter. Many of these cases would fall into the 2008 WHO category of 'B-cell lymphoma unclassified, with features intermediate between BL and diffuse large B-cell lymphoma' (BCLU). Patients with BCLU or BLL, especially those with dual t (8;14) and t(14;18) translocations leading to overexpression of Myc and bcl2, respectively, have inferior outcomes. 4, 5 A recently described algorithmic approach based on morphology and immunohistochemistry, and previously described molecular signatures, aid in distinguishing these entities. [6] [7] [8] Owing to the high proliferation index and rapid doubling time, BL is best treated with short-duration, dose-intensive chemotherapeutic regimes that have minimum treatment delays and incorporate CNS prophylaxis. With these regimes, BL has been shown to be highly chemosensitive, and CR rates of up to 100% may be achieved (reviewed by Blum et al. 1 ). The regime of CODOX-M with or without alternating IVAC pioneered by McGrath et al. 9 resulted in EFS rates of 97%. The UK Lymphoma Group (UKLG) reported a 73% OS and 64% EFS at 2 years, with a modification of this regime in the LY06 study. 10 Other regimes, such as the Hyper-CVAD, French LMB and Vanderbilt protocols, have achieved comparable response rates. [11] [12] [13] [14] [15] The incorporation of rituximab has been shown to further improve outcomes.
predate the development of intensive rituximab-containing protocols, and this limits the applicability of their conclusions. Furthermore, many of these studies include pediatric patients who have better outcomes. 13 Given these limitations of the available literature, it is difficult to be prescriptive about the suitability, timing and type of SCT, although some broad recommendations can be made to assist clinicians who will continue to be faced with situations where they need to make a decision in patients who are often young and have a tumor that is highly aggressive.
Identifying high-risk patients as potential candidates for transplantation Patients with BL are not a homogenous group. Indeed, in the LY10 study that was conducted by the United Kingdom Medical Research Council (MRC) and the National Cancer Research Institute (NCRI) Lymphoma Clinical Studies Group, OS was 88% in the group defined as low risk, whereas it was only 52% in the high-risk group, with a PFS of 49% in the latter. 19 Although it would be advisable to identify high-risk patients at presentation and for them to be discussed in the context of a transplant multidisciplinary meeting, there is no consensus as to how to identify this subset of patients. A number of high-risk parameters have been identified in studies and trials have varied in how they risk stratify patients (Tables 1 and 2 ). Many studies have used the International prognostic index (IPI) or age-adjusted IPI for risk stratification. 20 Most studies identify a raised serum lactate dehydrogenase (LDH) and bulky disease (mass 410 cm) as highrisk features; age 440 years has also been noted to be a poor prognostic feature. 21 However, up to 90% and 80% of patients may have an elevated serum LDH and stage III-IV disease, respectively, and stratifying on the basis of these parameters may not allow sufficient discrimination between subsets of patients. 9, 14, 19, 22, 23 A recent Swedish population-based study derived a score based on age 440 years, performance status 41 and serum LDH 4upper limit of normal to be significant in predicting survival in multivariate analysis of 156 adult patients with BL treated between 2000 and 2010. Although such a score may serve as a useful tool in risk stratifying patients who have been treated with current regimes, further validation would be desirable, especially in the context of patients undergoing SCT. 24 Summary: Although there is no consensus risk stratification for BL, patients identified as high risk-on the basis of either IPI/aaIPI or other risk scores applied at given centers-should be discussed in the setting of transplant multidisciplinary meeting for consideration of a potential SCT in the future.
AUTO-SCT IN BL
Auto-SCT in BL has been reported both in the upfront and in the refractory/relapsed settings in patients with BL. A variety of conditioning protocols have been applied, with BEAM-and TBIbased regimes being the most common (Tables 3 and 4) . Conditioning regimes for aggressive lymphomas have been reviewed, and there is little evidence to advocate one form of conditioning over another. 25 Factors guiding the choice of regime would include a center's familiarity with given protocols and individual patient-and disease-related factors.
Is there a role for upfront auto-SCT in BL? In a pilot study, the group from the City of Hope Hospital administered high-dose therapy (HDT) and auto-SCT in 52 patients with high-risk aggressive lymphoma (as defined by the IPI score) in CR or PR. Ten patients were classified as having small noncleaved cell lymphoma (SNCL), comprising patients with BL and BLL. OS and disease-free survival were 84 and 82%, respectively, for all patients. In the SNCL group, OS and disease-free survival were both 60% at 3 years. 26 These outcomes demonstrated the safety and feasibility of upfront auto-SCT in high-risk patients.
A number of prospective randomized studies have investigated the role of upfront HDT and auto-SCT in aggressive NHL, although only a few of these studies included patients with BL, and these too in small numbers. [27] [28] [29] A Cochrane review of the role of upfront HDT/auto-SCT in aggressive NHL concluded that there was no benefit to auto-SCT over chemotherapy, although not all studies reviewed included patients with BL. 30 Prospective studies in selected BL patients have reported only modest outcomes with upfront SCT. It should be noted, however, that these studies were not designed to directly compare chemotherapy with an autograft. Analysis of the LMB trial in adult BL patients found that patients who underwent transplantation in CR1 fared worse than those who received chemotherapy alone, although the transplant cohort of 18 patients included those who received autografts (n ¼ 11) and allografts (n ¼ 7), with 13 patients transplanted in CR1. 13 A Swiss study of 26 patients with highly aggressive NHLs comprising BL or lymphoblastic lymphoma, treated between 1987 and 1994, investigated the role of weekly chemotherapy followed by HDT/ auto-SCT. 31 The 3-year EFS in the BL group was 44%, which was inferior to contemporaneous published outcomes with chemotherapy alone. The Vancouver unit reported 43 patients with BL who were offered a form of transplantation upfront; 27 patients received a transplant (21 auto-SCTs, 6 allo-SCTs).
32 Three-year EFS was 51% for patients who underwent SCT, suggesting that SCT did not improve on outcomes expected with chemotherapy alone. However, the patient numbers were small and induction chemotherapy was heterogeneous, including nonintense CHOP-like regimens.
What these studies demonstrated was that, as in other aggressive NHLs, a planned upfront auto-SCT preceded by less intense induction in BL does not obviate the need for early doseintensive chemotherapy, and it is the latter that is crucial for achievement of a sustained remission. 33 Better results of upfront auto-SCT in BL were reported by the Dutch-Belgian Hemato-oncology Cooperative group (HOVON) who treated 27 patients with BL or BLL in a single-arm prospective study. Although 24 (89%) of the BL patients were at high risk, as defined by the UK Lymphoma Group, those with BM and CNS involvement were excluded. Patients received two high-dose sequential induction cycles-notably with higher cumulative dose of CY (4 g) than studies referred to above-and were included if they were at least in a PR after second induction. 34 Patients then received a BEAM-conditioned auto-SCT. The 5-year OS and EFS were 81 and 73%, respectively, and there were no toxic deaths.
An argument in favor of upfront auto-SCT, especially in those with high-risk features at presentation and hence at a higher risk of relapse, is that in patients receiving an auto-SCT outcomes for those transplanted in first CR are superior to those transplanted in more advanced disease states. The European Group for Blood and Marrow Transplantation (EBMT) carried out a retrospective registry study of 117 adult patients with BL who received an autograft between 1984 and 1994. 35 Eighty-two percent of patients were in CR or PR and 70 patients (60%) were in CR1. The 3-year actuarial OS and PFS for the latter group of patients was 72 and 73%, respectively, whereas for patients in chemosensitive relapse OS was 34%. In this study, disease bulk was predictive of outcome, and patients with a mass o5 cm had a 3-year actuarial PFS of 100%, 5-10 cm of 80% and 410 cm of 61%. although there was an advantage in PFS for TBIvs chemotherapy-based conditioning (70 vs 43%), this benefit was not retained in multivariate analysis. Gajewski et al. 36 reported outcomes of a large number of patients (n ¼ 241) with BL who received a SCT (113 auto-SCT, 128 allo-SCT) between 1985 and 2007, as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The 5-year PFS was 78% in the auto-SCT cohort for the 42% of patients who received an auto-SCT in CR1.
Using a response-adapted strategy following initial cycles of chemotherapy may help identify patients who might benefit from upfront auto-SCT. Although not currently a part of routine recommendations in BL, 37 performing interim and end-oftreatment FDG-PET scanning seems to be an attractive strategy to try to identify patients who may have a suboptimal response to initial chemotherapy and could help select patients who may derive benefit from upfront HDT. FDG-PET has been shown to be of value at diagnosis, interim assessment and on completion of therapy in patients with BL. 17, 38 Summary: Although there is insufficient evidence to advocate an auto-SCT in CR1, it is a clinical option in selected patients with high-risk features or those who have a poor response to the initial cycles of chemotherapy. 14, 39 An upfront auto-SCT should also be considered in patients who only achieve PR after completion of upfront chemotherapy. 17, 38 Further studies are required to delineate the role of FDG-PET. For a cohort with highly aggressive NHL.
Role of hematopoietic SCT in BL SO Ahmed et al
Auto-SCT in relapsing and refractory BL Given the favorable outcomes with current chemoimmunotherapeutic regimes, patients are most likely to encounter treatment with auto-SCT in the refractory and/or relapsed settings. When relapses do occur, they usually occur within the first year. 10, 13 Although the widely quoted Parma study demonstrated a benefit of HDT/auto-SCT over conventional chemotherapy in a study of 215 patients with relapsed NHL, it included only 1 patient with SNCL who received a transplant. 40 Many years before this, in 1978 the group at the National Institute of Health had reported outcomes of 14 adult and pediatric cases of refractory and/or relapsed BL who underwent HDT with BCNU/cytarabine/CY/6-thioguanine conditioning; only 8 patients received an auto-SCT. 41 In this study, there were four treatment-related deaths and only three long-term survivors.
Subsequent studies have shown that in patients with chemosensitive relapse auto-SCT can be expected to salvage around a third of patients, and only a minority benefit from this procedure if they have chemoresistant relapse or chemorefractory disease. Nademanee et al. 42 reported a single institution's experience of auto-SCT in 264 patients with poor-risk and relapsed intermediate-and high-grade NHL. The cohort included 28 (11%) patients with SNCL. The 5-year OS and PFS rates for the entire cohort were 55 and 47%, respectively; PFS for patients with relapsed disease was 34%. However, overall, patients with high-grade NHL including SNCL had a survival rate inferior to those with intermediate-grade lymphomas. The EBMT study demonstrated that for BL patients transplanted in chemosensitive relapse the 3-year OS was 37%. Patients who had chemoresistant disease had a dismal outcome, with an OS of only 7%. 35 Similarly, the report of Gajewski et al. 36 showed the 5-year PFS of those receiving an auto-SCT beyond CR1 to be 27%. In the Vancouver study, patients with progressive disease at the time of transplant died within 3 months of transplantation. 32 The impact of refractory disease on survival in these reports is similar to that in an EBMT study of pediatric patients with BL undergoing HDT/auto-SCT, in which patients with primary refractory disease or those with resistant relapse did not survive beyond 1 year. 43 
Summary:
The aim in patients with BL who relapse should be to administer intensive chemoimmunotherapy in order to achieve a second CR followed by early SCT. An auto-SCT may be expected to lead to sustained remission in 30-40% of patients. Although not precluding an autograft, chemorefractory or progressive disease despite optimal therapy may be better managed by enrolling patients in a clinical trial with novel agents, possibly including radioimmunoconjugates, or considering an allo-SCT, as most of these patients are unlikely to derive a long-term survival benefit from an auto-SCT.
ALLO-SCT IN BL
Patients with aggressive disease and those who have BM involvement or fail to mobilize adequate CD34 þ cells may benefit from an allo-SCT. Although allogeneic transplantation in high-risk lymphoma has been reported to be associated with an OS of 50-60%, few studies have investigated the role of allografts in BL. 44, 45 Reports including allo-SCT in BL are summarized in Table 4 .
Although it would be rare for patients to receive upfront allo-SCT with modern regimes, relatively favorable outcomes have been reported in a small number of patients in older studies. Troussard et al. 46 reported on nine patients with BL with CNS (n ¼ 7) and/or bone marrow (BM) (n ¼ 8) involvement who received allo-SCT with CY/TBI conditioning in CR1 between 1985 and 1989. The OS for this high-risk cohort was relatively favorable at 78%, with a median follow-up of 43 months.
Although allo-SCT has been studied in the treatment of recurrent lymphoma, patients with BL make up small numbers in these reports. Hamadani et al. 47 reported outcomes in 46 patients with chemorefractory, aggressive NHL (including three patients with BL); 39 received matched sibling allografts. OS and PFS at a median of the 5-year follow-up were 38 and 34%, respectively. Patients with progressive disease had a poor outcome, with an OS of 21% and PFS of 7%. Overall nonrelapse mortality (NRM) was 34%.
A retrospective EBMT registry study by Peniket et al. 48 analyzed outcomes in 1185 patients who received an allo-SCT lymphoma. The analysis included 71 (6%) cases of BL. Seventy-nine percent of the BL patients had stage III/IV disease, 16% had CNS involvement, 63% were transplanted in CR, with 38.5% in CR1 and 25% in CR41, and 20% were chemoresistant. The median OS and PFS for BL patients were 4.7 and 2.5 months, respectively; the actuarial OS and PFS at 4 years were 37 and 34.9%, respectively. Procedurerelated mortality was not insignificant at 30.9%. In multivariate analysis, status at transplant was the most significant prognostic factor.
In Europe and north America, only one-third of patients would be expected to have an HLA-matched sibling donor, and an allo-SCT may only be possible with an alternative donor. Van Besien et al. 49 reported a CIBMTR analysis of 283 matched unrelated donor transplants in NHL, including 68 (24%) patients who had lymphoblastic lymphoma/BL/BLL. Although this was a heterogeneous group, patients in this cohort had a significantly increased relative risk of treatment-related mortality (TRM) (relative risk (RR) of 1.97) and disease progression/relapse (RR 3.53) compared with those with follicular lymphoma; relapse accounted for 39% of deaths in the former group. Volunteerunrelated donor transplants had an inferior outcome to sibling transplants (PFS 22 vs 30%) in the report of Gajewski et al.
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These studies emphasize the significant toxicity of allo-SCT in what is likely to be a group of heavily pretreated patients, and hence the need to appropriately select patients bearing the risk of NRM in mind. In this regard, the hematopoietic SCT comorbidity index score has been predictive in a number of transplant settings and may assist in guiding patient selection. 50 Reduced-intensity conditioned (RIC) allo-SCT in BL Although there may be a role for RIC allo-SCT for BL, chemosensitivity and cytoreduction should be part of treatment considerations to avoid progression of disease before development of a GVL effect. 51 Generally, aggressive lymphomas with high proliferation kinetics are generally less susceptible to the effects of GVL, and would be expected to have inferior outcomes when compared with indolent lymphomas such as follicular lymphoma.
52 RIC allo-SCT may still, however, have a role in patients relapsing after auto-SCT, especially if age, comorbidity or the effect of cumulative toxicity of prior therapy preclude a myeloablative allograft, and if the disease is not rapidly progressive. 53 Patients with chemoresistant or aggressive lymphomas have poorer outcomes as compared with low-grade NHL and chemosensitive disease after RIC allografts, with a PFS of only 12.9% at 2 years reported in a retrospective EBMT study. 54 T-cell-depleted RICs also show worse outcome for high-grade compared with lowgrade lymphomas. 55, 56 In patients receiving a RIC allograft from an alternative donor, a diagnosis of BL, BLL or lymphoblastic lymphoma has been associated with an increased relative risk of treatment failure (2.11), and high-grade histology was associated with a lower PFS. 57 A strategy of tandem auto-SCT-RIC in relapsed and transformed aggressive NHL has been trialed with encouraging results and would require validation in BL patients in whom disease control can be achieved. 58 Summary: In the presence of a matched sibling or fully matched unrelated donor, allo-SCT is a clinical option in BL patients relapsing after first-line therapy, especially if occurring within 12 months, and in those who have received multiple lines of prior therapy, including those who may have received a prior auto-SCT, and in those with marrow involvement or failed mobilization of CD34 þ cells. Long-term survival may be achieved in 30-35% of patients; however, there is a significant NRM of approximately 30% in these patients. Mismatched alternate donor transplants are not recommended. The role of RIC and T-cell-depleted transplants in BL requires further evaluation.
ALLO-SCT VS AUTO-SCT
The need to decide on whether to opt for an auto-SCT or allo-SCT often arises in the relapsed setting. Patients receiving an allo-SCT are likely to be more heavily pretreated-a source of bias when comparing these groups. Patients relapsing after having received a prior auto-SCT would, in the presence of a suitable donor, usually proceed to an allo-SCT where feasible. The advantage of an allo-SCT is the infusion of a tumor-free graft and having the option of administration of DLI to manage post-transplant relapse. 37 Some patients may not be suitable for an auto-SCT because of BM involvement or because of a failure to adequately mobilize peripheral blood stem cells and thus be candidates for allo-SCT. In addition, patients relapsing after modern intensive regimes that include rituximab represent a subset of patients with highly aggressive disease, and an argument in favor of an allo-SCT in part hinges on the presence of a GVL effect. This potential benefit, however, is offset by the higher NRM associated with allo-SCT and the occurrence of severe acute and chronic GVHD.
As in other lymphomas, there are few prospective studies that are able to provide sufficient evidence to lend support to favor one form of transplant over another. Biermaen et al. found no evidence for a GVL effect in a comparison of allogeneic, syngeneic and autologous transplants in NHL. 59 Although the graft-versus-BL effect has been reported in myeloablative and RIC settings, these have only been published as single case reports. 60, 61 A single institution study found no difference in outcome between auto-SCT and CY/TBI conditioned allo-SCT in 38 patients with BL; OS was 23% and 31%, respectively (P ¼ NS), with wide confidence intervals and small numbers. 80 The aforementioned EBMT study of Peniket et al.-which included a matched-pair analysis comparing the allo-SCT with auto-SCT-demonstrated that in patients transplanted for BL OS was superior with auto-SCT than with allo-SCT; it is noteworthy that there was no significant difference in relapse rates. 48 Although the study was a comparison of first transplants, and thus excluded patients who may have had an allo-SCT after a failed auto-SCT, there were significant differences in the number of lines of therapy in the auto-SCT and allo-SCT groups, with 55.3% receiving three or more lines of treatment in the former versus 65.1% in the latter (P ¼ 0.003).
In the CIBMTR report of Gajewski et al., 5-year OS rates (with 95% confidence intervals) were 54% (44-63%), 32% (22-43%) and 23% (12-36%) for auto-SCT, sibling allo-SCT and unrelated/ mismatched donor allo-SCT groups, respectively. 36 Although the 5-year PFS for auto-SCT appeared to be superior to allo-SCT in CR1 (78 vs 50%) and beyond CR1 (27 vs 19%) , statistical significance of the differences was not reported. There was a significant NRM in the allo-SCT cohorts (26% in sibling, 28% for mismatched or unrelated). The groups were not homogenous, with a higher proportion of patients receiving auto-SCT being in CR1 as compared with those undergoing a sibling allo-SCT or mismatched/unrelated allo-SCT (42, 34 and 6%, respectively) .
Preliminary data of the EBMT for patients receiving either an auto-SCT (n ¼ 1352) or allo-SCT (n ¼ 322) between 1979 and 2009 suggest that the OS for auto-SCT patients is superior to allo-SCT for all categories of patients at 5 years (5-year OS 59 vs 35%, PFS 55 vs 33%) (Personal communication, P. Dreger). Further analysis of these outcomes-especially of SCTs carried out in the rituximab-era-is required before any conclusions or recommendations can be made, and data for an EBMT study are currently being collected to try to address this question.
Although retrospective registry data seem to point to a benefit of auto-SCT, what is lacking-and would be challenging to produce-is evidence in the form of a prospective comparison of auto-SCT and allo-SCT in patients with refractory or relapsed BL. Improvements in allo-SCT survival rates would require a further reduction in the NRM associated with this procedure, and continued improvements in patient and donor selection, conditioning regimes and supportive care may help tip the balance in favor of allo-SCT.
Summary: In relapsed patients achieving a second response to chemotherapy, an auto-SCT may be a suitable option; although allo-SCT is associated with a tumor-free graft and the possibility of a GVL effect, it is associated with a higher NRM, and retrospective registry data point to an inferior OS when compared with auto-SCT, particularly for first transplants. Allo-SCT is an alternative option if a matched sibling or fully matched alternate donor is available, especially if an auto-SCT is not feasible.
TRANSPLANTATION IN BCLU
Patients with BCLU have very aggressive disease and a particularly poor outcome, as do patients who would have been labeled BLL in prior classifications; this latter group had been shown to have outcomes inferior to those of DLBCL, with a median survival of 2-7 months. 4 Thomas et al. reported a higher incidence of complex cytogenetics and abnormalities of BCL2 (the 'double hit lymphoma' [DHL]) in elderly patients treated with Hyper-CVAD; this subset had a worse outcome. 11 Patients with DHL or the 'triple-hit' lymphomas (THL), which have an additional abnormality of BCL6, have a very poor outlook, with a median survival of 6 and 4 months, respectively. 62,63 Tholouli et al. described 13 patients with a diagnosis of BL who had bone marrow involvement with complex cytogenetics, many with t(14;18). Four patients underwent transplantation (two sibling allo-SCT, one matched unrelated donor allo-SCT and one auto-SCT). All patients died within 2 months of completion of therapy. Johnson et al. described 54 such patients, 6 of whom had HDT and 4 of whom went on to have a transplant (3 auto-SCTs, 1 allo-SCT). The median survival for these patients was 3 months despite intensive therapy. A low IPI score, the absence of BM involvement, DLBCL histology, a non-IG/MYC translocation and BCL2 negativity were associated with a less unfavorable outcome. 64 Dann et al. published data on 27 patients with relapsed or refractory NHL (4 with BLL) who underwent allo-SCT. 65 Eleven (41%) died of NRM and nine (33%) of lymphoma, pointing to the significant morbidity and mortality in heavily pretreated patients. Of nine high-grade patients, only one survived.
A number of centers have reported transplants in small numbers of patients with this subtype of NHL (Table 5) , and transplantation does not seem to mitigate the very poor prognosis of these patients, especially in those with DHL or THL, and only a minority of selected patients derive a survival benefit. More aggressive strategies including immunological therapies will need to be developed to achieve remissions in these patients. Many a time, the sheer aggressiveness and chemorefractory nature of this presentation does not allow the patient or physician to opt for anything other than a palliative approach. 4 Summary: Patients with BCLU or DHL have aggressive disease and an outcome inferior to those with BL even with transplantation. Although a minority of patients may benefit from transplantation, others should be considered for clinical trials with novel therapies, and in others supportive care may be the only option.
SCT IN HIV þ BL BL accounts for approximately 30% of all HIV-associated lymphomas, 2 and in North America nearly 70% of adult BL cases are estimated to be HIV þ . 66 Outcomes in HIV þ BL patients treated with intensive chemotherapy have been shown to be similar to those who are HIV negative (HIV À ), albeit with increased acute toxicities. 67 Earlier studies investigating SCT often excluded patients who have been HIV þ , although subsequent studies have demonstrated that outcomes in these patients are not inferior to those of HIV À patients (Table 6) . 16, 68 Balsalobre et al. 69 published data on 68 patients with HIV-related lymphoma reported to the EBMT who had undergone auto-SCT with BEAM (95.5%)-or TBI-(4.5%) based regimens; 8 patients (16%) had BL or BLL. For the entire cohort, PFS and OS were 56.5 and 61%, respectively. A worse outcome was portended by chemorefractory disease, which resulted in a PFS of only 3 months. There was a nonsignificant trend for patients with NHL other than DLBCL to have a worse outcome. A matched-pair analysis of the EBMT of 53 HIV þ patients with an equal number of HIV-patients with NHL and HL revealed no significant difference in NRM, OS or PFS in the HIV À and HIV þ groups, indicating that in the era of HAART HIV positivity need not be a contraindication to auto-SCT. 70 HIV þ patients with high-risk disease at presentation, or those with relapsing or refractory disease have also been shown to have encouraging outcomes. The group at the City of Hope Hospital performed auto-SCT on 20 such patients, 6 (30%) with BL. Seventeen patients (85%) were alive at the 31-month follow-up. 71 Although allo-SCT in a range of hematological malignancies including NHL has been reported to be feasible in a cohort of HIV þ patients, its role needs to be evaluated further in HIV þ BL.
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Summary: Patients with HIV þ BL have outcomes with auto-SCT not inferior to those who are HIV À , although with a slight increase in treatment-related toxicities. The place of allo-SCT in these patients requires further study.
CONCLUSIONS AND FUTURE DIRECTIONS
Given the limitations of the available evidence, a decision to incorporate SCT in the treatment of patients with BL should be carried out in a multidisciplinary setting. Ideally, patients should be treated in the context of a clinical trial. SCT is not likely to benefit patients presenting with low-risk chemosensitive disease, and these patients should receive treatment according to an intensive chemotherapy protocol with rituximab. However, in the presence of high-risk features or poor response to initial chemotherapy, a form of transplant may be considered upfront. 73 Risk of long-term toxicities of HDT/auto-SCT such as myelodysplasia and secondary malignancies should be considered, especially in younger patients.
In the setting of relapsed or refractory BL, the aim should be the achievement of a second remission, followed by a form of transplantation. Auto-SCT has a lower NRM and, although allo-SCT is not currently part of upfront treatment algorithm, it may be considered as a clinical option in CR2. Indeed, the EBMT recommendations allow for its use as a clinical option in CR1, although patients should be carefully selected. 39 Given the disease dynamics of BL, the role of RIC transplants needs further evaluation, and there is insufficient evidence to favor T-celldepleted allo-SCTs.
It would be reasonable to anticipate that advances in diagnostics, response assessment and novel therapies will help to further improve outcomes in patients with high-risk BL. There is Refinements in treatment algorithms may be assisted by molecular diagnostic techniques that help separate BL from BCLU and DLBCL and provide molecular markers for risk stratification. Minimal residual disease (MRD) monitoring during follow-up may help identify those who may have a higher risk of relapse and early treatment intensification; further studies and validation are required to define the place of MRD monitoring in treatment planning. [74] [75] [76] The role of monoclonal antibodies including rituximab and newer agents in conditioning regimes is expanding, and reports of outcomes for patients treated with these regimes are awaited in the hope that they will further improve on treatment strategies and outcomes in these patients. 
